The suggestion that elevated IGF-1 levels may serve as a marker of risk has been long established [65,66], however several studies reported conflicting results, suggesting that IGF-1 was only a tumor marker rather than an etiologic factor in prostate cancer and as such was unsuitable as a long-term predictor of the disease [67,68,69,70]. This evidence concerns the gene IGF1 and neoplasm.